UK markets closed

Zogenix, Inc. (ZGNX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
21.29+0.29 (+1.38%)
At close: 4:00PM EDT
Sign in to post a message.
  • S
    SAN
    A good company is what creates a value for you. Zogenix has the institution holding, has a good record but recent evaporation of its stock price has eroded all investors confidence. The bottom line is no matter how ambitious or pipeline is, it has to have the resilience.There are too many companies, on the other hand, like $6 but they haven’t dipped as much. People who invested with a lot of trust in this, see they being deceived. Hope somewhere the management sees this post to understand this sooner to curb this falling knife. I am sure patience has its limits and no matter what you do after a certain threshold things never come back or in the best case takes years. So Zogenix has to show the resilience and management has to work hard in either buying back or other capabilities to bring back the investor confidence. I can’t stress more on that.
  • D
    David
    EMA APPROVAL!
  • M
    Mr. Clean
    Oh we got some good news!
  • S
    SAN
    Institutional buying has been active but the share price has been going down for past several weeks.How is that happening is what I am trying to understand. Can some one who is long, chime in please on the prospects of this. Thanks in advance.
  • A
    Art Vandelay
    Earnings report date?
  • T
    Terrance
    And this stock is still undervalued. Get in now before it takes off
  • M
    Mr. Clean
    Company could care less about its shareholders
  • f
    fred
    No bump from the WMS data presentation.@&@&$&@:
  • D
    David
    World Muscle Society 2020 Congress presentation tomorrow, Thu, 5:30pm, 10/1, on MT1621 TK2 deficiency drug update. The Congress is all virtual. Wall Street is following closely. Look for good press Fri or next week.
  • D
    David
    Results corroborate highly statistically significant convulsive seizure reductions seen in earlier multinational Phase 3 studies of FINTEPLA in Dravet...
    Results corroborate highly statistically significant convulsive seizure reductions seen in earlier multinational Phase 3 studies of FINTEPLA in Dravet...
    www.globenewswire.com
  • 💊C
    Zogenix passed 3rd P3 trial in Dravet w usual 65% adjusted reduction. This one enables them to submit NDA in Japan.
  • D
    David
    https://finance.yahoo.com/news/hedge-funds-never-bullish-zogenix-163356456.html

    38 of the largest hedge funds are bullish on ZGNX. A record. 🚀
  • 💊C
    The offering is more bond-like w a great 2.75% rate, but there is probably a future dilute coming. Q3 earnings may disappoint due to timing of the raise so hold on tight.
  • D
    David
    Zogenix initiated with a Market Perform at Raymond James Raymond James analyst Danielle Brill initiated coverage of Zogenix with a Market Perform rating. The analyst notes that the company's launch of Dravet Syndrome drug Fintepla comes at a "very inopportune time" given the COVID-19 related headwinds in addition to the competitive dynamic in DS and the drug's REMS requirements for new patients. Brill contends that near-term upside for Zogenix is limited.

    Read more at:
    https://thefly.com/n.php?id=3150703
    Raymond James initiates analyst coverage $55 PT
    Zogenix initiated with a Market Perform at Raymond James Raymond James ZGNX
    Zogenix initiated with a Market Perform at Raymond James Raymond James ZGNX
    thefly.com
  • S
    SAN
    Pattern recognition: it will be stable for few days and all of a sudden drop drastically, locking in investors at lower levels. It dropped from $53 to 45 to 24 to 18. If you look at the graphs, it was $4 lower yesterday but never went up unlike other stocks and remained at that level only. Today, it has been hovering around 17.45.
  • M
    Mr. Clean
    Buyout coming
  • D
    David
    Ligand inks deal to acquire Taurus and xCella Biosciences. Zogenix reports positive data from pivotal Phase 3 clinical trial.
    Ligand inks deal to acquire Taurus and xCella Biosciences. Zogenix reports positive data from pivotal Phase 3 clinical trial.
    seekingalpha.com
  • 💊C
    This video gives an overview of Fintepla and Zogenix Central. Zogenix appears to have been very well prepared for launch. https://www.youtube.com/watch?v=Z476fM0dtsU&t=1s
    FINTEPLA overview and Zogenix Central Patient Services Program
    www.youtube.com
  • j
    jung
    I was looking to bottomfishing today but I just saw a block sale of almost 7mil shares @$17,55. I'm not sure if it's a good sign or a bad one so I cancelled my buy order.